ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
find tumor cells and kill them or carry tumor-killing substances to them. Others interfere
with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of
tumor cells by blocking blood flow to the tumor. Giving ABI-007 together with bevacizumab may
kill more tumor cells.
PURPOSE: This phase II is studying how well giving ABI-007 together with bevacizumab works in
treating women with recurrent or metastatic breast cancer.